Gastrointestinal Tumor Research and Treatment
Gastrointestinal Tumor Research and Treatment is a research topic within Gastroenterology. Science Explorer counts 32k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the diagnosis and treatment of gastrointestinal stromal tumors (GISTs), including the efficacy and safety of targeted therapies like Imatinib Mesylate and Sunitinib, the role of PDGFRA and KIT mutations in GISTs, consensus approaches for management, surgical considerations, prognostic factors, use of EUS-guided fine needle aspiration, and the significance of succinate dehydrogenase (SDH) deficiency. It also explores the use of PET imaging for response evaluation.
- Imatinib Mesylate
- Sunitinib
- PDGFRA Mutations
- KIT Mutations
- GIST Consensus Conference
- Surgical Management
- Prognostic Factors
- EUS-guided Fine Needle Aspiration
- SDH Deficiency
- PET Imaging
- Research works
- 32k fractional, since 1950
- In the world top 10%
- 3.3k per year above
- Top-10% rate
- 10.2% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- +6% the tick is no change
- Largest producer
China
29% of the 10 largest, 2022-now
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Gastrointestinal Tumor Research and Treatment research?
By volume, China and the United States publish the most (1.5k and 1.2k works in 2022-now).
By volume, 2022-now
- 1
China 1.5k works
- 2
United States 1.2k works
- 3
Japan 893 works
- 4
India 312 works
- 5
South Korea 250 works
- 6
Italy 249 works
- 7
United Kingdom 193 works
- 8
Germany 191 works
- 9
Spain 156 works
- 10
France 137 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Gastrointestinal Tumor Research and Treatment research?
By volume in 2022-now, Sun Yat-sen University publishes the most Gastrointestinal Tumor Research and Treatment research, followed by Sichuan University and Harvard University.
By volume, 2022-now
- 1
Sun Yat-sen University
China 65 works
- 2
Sichuan University
China 50 works
- 3
Harvard University
United States 42 works
- 4
Nanjing Medical University
China 42 works
- 5
Zhejiang University
China 39 works
- 6
Fujian Medical University
China 38 works
- 7
Fudan University
China 38 works
- 8
Shanghai Jiao Tong University
China 37 works
- 9
Peking University
China 37 works
- 10
Mayo Clinic
United States 32 works
Who are the leading researchers in Gastrointestinal Tumor Research and Treatment?
The most-cited researchers publishing on Gastrointestinal Tumor Research and Treatment include Guido Kroemer, Gad A. Getz and Jun Wang.
- 1
Guido Kroemer
France 386k citations
- 2
Gad A. Getz
United States 364k citations
- 3
Jun Wang
China 340k citations
- 4
Matthew M. Meyerson
United States 280k citations
- 5
Chris Sander
United States 276k citations
- 6
Hagop M. Kantarjian
United States 273k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Gastrointestinal Tumor Research and Treatment research done?
The largest centres of Gastrointestinal Tumor Research and Treatment research in 2022-now are Tokyo (Japan), Beijing (China), Shanghai (China) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Kashiwa.
Largest cities, 2022-now
Where it is the local speciality
- KashiwaJP · 23.7 works41×
Location quotient: how much more of its research is in Gastrointestinal Tumor Research and Treatment than the world average.
Where is the best place to study Gastrointestinal Tumor Research and Treatment?
Among universities, judged by research, Harvard University, Sun Yat-sen University and Humanitas University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in Gastrointestinal Tumor Research and Treatment, country by countryIs Gastrointestinal Tumor Research and Treatment research growing?
Output in 2022-2025 was 6% higher than in 2018-2021, peaking in 2024. The fastest-growing topics are Gastrointestinal Tumor Research and Treatment.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Gastrointestinal Tumor Research and Treatment as a percentage of every work published that year, 0.028% in 2024.
Fractional works of Gastrointestinal Tumor Research and Treatment over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about Gastrointestinal Tumor Research and Treatment. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.